By Fineline Cube 
Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci) announced a strategic partnership with ALK (ALKB:DC / OMX: ALK B) to develop and commercialise ALK’s house‑dust‑mite (HDM) allergy immunotherapy (AIT) products in Mainland China. Under the agreement, GenSci will hold exclusive rights to ALK’s injectable Alutard HDM, skin‑prick tests, and the ACARIZAX sublingual tablet through the end of 2039.
Partnership Highlights
- Exclusive Distribution: GenSci obtains sole mainland China rights to Alutard HDM, associated diagnostic tests, and ACARIZAX.
- Marketing & Development: GenSci will cover all marketing, sales, and the majority of clinical‑development and registration costs; ALK will supply and manufacture the products.
- Immediate Roll‑out: Alutard sales begin immediately, with ACARIZAX added to GenSci’s portfolio upon regulatory approval.
- Joint Clinical Development: Both parties will finalise ongoing clinical studies to expedite ACARIZAX approval for adults and children.
Financial Terms
- Up‑front Payment: DKK ≈ 245 million to ALK.
- Regulatory Milestones: Up to DKK ≈ 300 million tied to ACARIZAX approval (2028‑2030).
- Commercial Milestones: Up to DKK ≈ 780 million contingent on future in‑market sales in Mainland China.
Strategic Implications
- Market Access: The partnership positions GenSci to capture the growing Chinese AIT market, estimated to exceed US$1 billion by 2030.
- Portfolio Expansion: Adding ACARIZAX to GenSci’s product line diversifies its offerings beyond injectable therapies.
- Collaborative Development: Joint clinical efforts may shorten time‑to‑approval, providing a competitive edge over other AIT providers.-Fineline Info & Tech